In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known ...
FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide ...
Last week, the FDA said Lilly had sufficiently met demand for its tirzepatide products, Mounjaro and Zepbound, so they are no longer in short supply ‒ meaning compounding pharmacies will soon have to ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...